Vyalev — Medical Mutual

Parkinson’s disease

Initial criteria

Patient is diagnosed with advanced Parkinson’s disease
Patient is experiencing 'off' episodes such as muscle stiffness, slow movements, or difficulty starting movements
Patient has an average 'off' time of at least 2.5 hours per day
Patient has tried Crexont OR Rytary (carbidopa-levodopa extended-release capsules) AND had significant intolerance OR inadequate efficacy, according to the prescriber
Patient has previously tried or is currently receiving ONE other treatment for 'off' episodes (e.g., entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys [opicapone], or Xadago [safinamide])
Medication is prescribed by or in consultation with a neurologist

Patient is diagnosed with advanced Parkinson’s disease
Patient has tried Crexont OR Rytary (carbidopa-levodopa extended-release capsules) AND had significant intolerance OR inadequate efficacy, according to the prescriber
Patient has previously tried or is currently receiving ONE other treatment for 'off' episodes (e.g., entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys [opicapone], or Xadago [safinamide])
Medication is prescribed by or in consultation with a neurologist
There is clinically significant improvement or stabilization in clinical signs and symptoms of disease defined as an increase of on-time with a decrease in the number of off episodes compared to baseline

1 year